Passer au contenu principal
« Paris (French) accueil »« News accueil »
Story
« 26 de 50 »

Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue - Yahoo Finance

Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue  Yahoo Finance Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.  Yahoo Finance Pfizer’s modest 2026 outlook shows its big investments will take time to pay off  CNBC Pfizer’s stock drops after drug giant lowers its revenue forecast  MarketWatch Pfizer Forecasts Flat 2026 Sales as It Builds Drug Pipeline  Bloomberg.com

Latest News